We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Zentalis Pharmaceuticals Inc (ZNTL) USD0.001

Sell:$2.66 Buy:$2.79 Change: $0.085 (3.32%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$2.66
Buy:$2.79
Change: $0.085 (3.32%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$2.66
Buy:$2.79
Change: $0.085 (3.32%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Contact details

Address:
10275 Science Center Drive, Suite 200
SAN DIEGO
92121
United States
Telephone:
+1 (858) 2634333
Website:
https://www.zentalis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZNTL
ISIN:
US98943L1070
Market cap:
$182.44 million
Shares in issue:
71.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Scott Myers
    Chairman of the Board
  • Julie Eastland
    President, Chief Executive Officer, Director
  • Vincent Vultaggio
    Senior Vice President, Finance, Interim Principal Accounting Officer and Principal Financial Officer
  • Wendy Chang
    Chief People Officer
  • Mark Lackner,
    Chief Scientific Officer
  • Ingmar Bruns
    Chief Medical Officer
  • Haibo Wang
    Chief Business Officer
  • Andrea Paul
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.